[클리니컬 히스토리] 엑세스바이오, 변이 대응 확인…키트 재가동 시험대

Accessbio's validation that its CareSuprb diagnostic kit maintains effectiveness against emerging COVID-19 variants highlights a critical industry challenge: diagnostic manufacturers must evolve beyond pandemic-dependent revenue streams. With COVID-19 diagnostics revenue collapsing from 92% to just 8% of total sales and production capacity down to 1%, the company's future hinges on portfolio expansion into respiratory illness detection and securing stable public procurement contracts.